文献速递前列腺癌

双参数与多参数磁共振成像诊断临床显著前列腺癌的比较:一项国际配对非劣效确证性观察者研究

Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.
PubMed 文献 · Eur Urol · 2024-10-22

该国际多读者多病例观察者研究纳入4个欧洲中心的400例多参数MRI检查,比较双参数MRI与多参数MRI诊断临床显著前列腺癌的非劣效性。结果显示双参数MRI在AUROC及PI-RADS≥3的敏感度和特异度上均非劣效于多参数MRI。作者结论认为双参数MRI在无既往临床显著前列腺癌发现及前列腺治疗史的人群中有应用价值,但需额外随机前瞻性研究探讨结果的普遍性。

要点

  • 双参数MRI诊断临床显著前列腺癌的AUROC为0.853,多参数MRI为0.859,非劣效差异为-0.6%。
  • PI-RADS≥3时双参数MRI敏感度88.6%、多参数MRI敏感度89.4%,非劣效差异-0.9%。
  • PI-RADS≥3时双参数MRI特异度58.6%、多参数MRI特异度57.7%,非劣效差异0.9%。

核心结论

  • 双参数MRI在临床显著前列腺癌诊断的AUROC及PI-RADS≥3的敏感度和特异度上非劣效于多参数MRI。
  • 双参数MRI在无既往临床显著前列腺癌发现和前列腺治疗史的个体中显示应用价值。
  • 需要额外的随机前瞻性研究来探讨结果的普遍性。

研究设计与样本

  • 国际多读者多病例观察者研究,纳入4个欧洲中心的400例多参数MRI检查。
  • 排除既往接受前列腺治疗或已有临床显著前列腺癌(Gleason分级≥2)发现的检查。
  • 读者依次评估双参数MRI和多参数MRI,给出病灶特异性PI-RADS评分(3-5)和患者水平怀疑评分(0-100)。
  • 参考标准采用组织病理学和≥3年随访。
  • 共62名读者参与,来自45个中心和20个国家。

主要发现

  • 临床显著前列腺癌患病率为33%(133/400)。
  • 双参数MRI与多参数MRI的AUROC分别为0.853(95%CI 0.819-0.887)和0.859(95%CI 0.826-0.893),非劣效差异为-0.6%(95%CI -1.2%至0.1%,p<0.001)。
  • PI-RADS≥3时,双参数MRI与多参数MRI的敏感度分别为88.6%(95%CI 84.8-92.3%)和89.4%(95%CI 85.8-93.1%),非劣效差异为-0.9%(95%CI -1.7%至0.0%,p<0.001)。
  • PI-RADS≥3时,双参数MRI与多参数MRI的特异度分别为58.6%(95%CI 52.3-63.1%)和57.7%(95%CI 52.3-63.1%),非劣效差异为0.9%(95%CI 0.0-1.8%,p<0.001)。
  • 在替代风险阈值下,多参数MRI以降低特异度为代价提高敏感度;决策曲线分析示多参数MRI路径在不愿患癌情形下净获益最高,双参数MRI路径在不愿活检情形下获益更大;亚组分析提示DCE MRI对非专家读者的额外获益有限。

关键数值与推荐

  • 非劣效界值为5%。
  • 主要终点为患者水平临床显著前列腺癌诊断的AUROC以及PI-RADS≥3时的敏感度和特异度。
  • 次要结局包括临床不显著前列腺癌(GG1)诊断、替代风险阈值下的诊断评估、决策曲线分析和考虑读者专业水平的亚组分析。

临床怎么用

  • 作者结论认为双参数MRI在无既往临床显著前列腺癌发现和前列腺治疗史的个体中显示应用价值,但需额外随机前瞻性研究探讨结果的普遍性。

局限性

  • 活检基于多参数MRI影像进行。
  • 阅片按顺序进行。
  • 需要额外的随机前瞻性研究来探讨结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Biparametric magnetic resonance imaging (bpMRI), excluding dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), is a potential replacement for multiparametric MRI (mpMRI) in diagnosing clinically significant prostate cancer (csPCa). An extensive international multireader multicase observer study was conducted to assess the noninferiority of bpMRI to mpMRI in csPCa diagnosis. METHODS: An observer study was conducted with 400 mpMRI examinations from four European centers, excluding examinations with prior prostate treatment or csPCa (Gleason grade [GG] ≥2) findings. Readers assessed bpMRI and mpMRI sequentially, assigning lesion-specific Prostate Imaging Reporting and Data System (PI-RADS) scores (3-5) and a patient-level suspicion score (0-100). The noninferiority of patient-level bpMRI versus mpMRI csPCa diagnosis was evaluated using the area under the receiver operating curve (AUROC) alongside the sensitivity and specificity at PI-RADS ≥3 with a 5% margin. The secondary outcomes included insignificant prostate cancer (GG1) diagnosis, diagnostic evaluations at alternative risk thresholds, decision curve analyses (DCAs), and subgroup analyses considering reader expertise. Histopathology and ≥3 yr of follow-up were used for the reference standard. KEY FINDINGS AND LIMITATIONS: Sixty-two readers (45 centers and 20 countries) participated. The prevalence of csPCa was 33% (133/400); bpMRI and mpMRI showed similar AUROC values of 0.853 (95% confidence interval [CI], 0.819-0.887) and 0.859 (95% CI, 0.826-0.893), respectively, with a noninferior difference of -0.6% (95% CI, -1.2% to 0.1%, p < 0.001). At PI-RADS ≥3, bpMRI and mpMRI had sensitivities of 88.6% (95% CI, 84.8-92.3%) and 89.4% (95% CI, 85.8-93.1%), respectively, with a noninferior difference of -0.9% (95% CI, -1.7% to 0.0%, p < 0.001), and specificities of 58.6% (95% CI, 52.3-63.1%) and 57.7% (95% CI, 52.3-63.1%), respectively, with a noninferior difference of 0.9% (95% CI, 0.0-1.8%, p < 0.001). At alternative risk thresholds, mpMRI increased sensitivity at the expense of reduced specificity. DCA demonstrated the highest net benefit for an mpMRI pathway in cancer-averse scenarios, whereas a bpMRI pathway showed greater benefit for biopsy-averse scenarios. A subgroup analysis indicated limited additional benefit of DCE MRI for nonexperts. Limitations included that biopsies were conducted based on mpMRI imaging, and reading was performed in a sequential order. CONCLUSIONS AND CLINICAL IMPLICATIONS: It has been found that bpMRI is noninferior to mpMRI in csPCa diagnosis at AUROC, along with the sensitivity and specificity at PI-RADS ≥3, showing its value in individuals without prior csPCa findings and prostate treatment. Additional randomized prospective studies are required to investigate the generalizability of outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Twilt JJ, Saha A, Bosma JS, et al. Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. Eur Urol. 2024. PMID: 39438187. doi:10.1016/j.eururo.2024.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。